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Summary
Data from the health survey for England 2006 [1], showed that the prevalence
of type 2 diabetes mellitus (T2DM) has more than doubled in men and women
since 1991. In the USA certain States have a prevalence of T2DM of greater
than 10% [2]. Globally it has been reported that this increase is by no
means slowing down and that the number of individuals with the disease is
expected to rise from 171 million cases reported in 2000 to 366 million by
the year 2030 [3]. Physical inactivity and obesity are two major risk factors
for the development of T2DM. In this review we will discuss evidence of an
association between physical inactivity, obesity and T2DM from prospective
cohort studies and clinical trials. We will also discuss some of the potential
mechanisms that are thought to link obesity and physical inactivity with the
major pathophysiological precursor of T2DM, insulin resistance. Copyright 
2009 John Wiley & Sons, Ltd.
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Prospective studies and clinical trials
Many prospective studies have been published over the last two decades
reporting strong associations between daily physical activity and a reduced
risk of developing T2DM (Table 1). Helmrich et al. investigated 5990
male alumni from the University of Pennsylvania and reported a negative
relationship between incidence of type 2 diabetes and physical activity [4].
Indeed, for every increase in leisure time energy expenditure of 500 kcal, the
age-adjusted risk for developing T2DM decreased by 6%. This relationship
held strong even when adjustments were made for obesity, hypertension
and a parental history of diabetes. These findings were later replicated in a
much larger cohort of women. The Nurses’ Health Study [5] followed 70 102
registered nurses and reported a progressive reduction in the age-adjusted
relative risk of T2DM with increasing physical activity.
Following on from these earlier studies, similar findings have been reported
in studies across the globe. Studies from the UK [6], Japan [7], Finland [8]
and Germany [9] have reported a reduction in relative risk for the devel-
opment of T2DM of between 15 and 60% with increased daily physical
activity. In addition, Hu et al. [8] displayed eloquently the relative risk of
developing T2DM with not only physical activity quintiles but also those of
body mass index (BMI) and impaired glucose regulation. The authors showed
that an increase in BMI drastically increased the relative risk for develop-
ment of T2DM whilst physical inactivity in normal weight individuals had a
Copyright  2009 John Wiley & Sons, Ltd.
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Table 1. Prospective studies implicating physical inactivity as a risk factor in the development of type 2 diabetes
Author Participants Comments Country of study
Helmrich et al. [4] 5990 M ↓ Age-adjusted risk of 6% every 500 kcal of leisure
time physical activity
US
Perry et al. [6] 7735 M ↓ Relative risk of 60% between moderately active
men and inactive men
UKa
Hu et al. [5] 70 102 W ↓ Relative risk of 26% between upper and lower
quintile of physical activity
USb
Nakanishi et al. [7] 2924 M ↓ Adjusted relative risk of 59% between upper and
lower quintile of physical activity
Japan
Hu et al. [8] 2017 M and 2352 W ↓ Adjusted relative risk of 15 and 57% between
moderate and high compared to low physical
activity
Finland
Meisinger et al. [9] 4069 M and 4034 W ↓ Adjusted relative risk of 13, 30 and 76% between
low, moderate and high compared to no physical
activity
Germanyc
M, men; W, women.
aBritish Regional Heart Study.
bThe Nurses’ Health Study.
cThe MONICA/KORA Augsburg Cohort Study.
much attenuated effect. Pooling the data they concluded
that those individuals with a BMI ≥30 kg/m2, partake in
low levels of physical activity, have impaired glucose
regulation and are 30 times more likely to develop type
2 diabetes than normal weight, active normal glucose
tolerant individuals. A similar finding was reported by
Weinstein et al. [10] who followed 37 878 women for an
average of 6.9 years. They concluded that both BMI and
physical inactivity were predictors of T2DM incidence,
but that the magnitude of the association with BMI was
greater than with physical inactivity.
In addition to the aforementioned prospective studies,
clinical trials, in which lifestyle modifications were made,
have reported that the addition of physical activity and
dietary modification can reduce the incidence of T2DM.
The Da Qing Impaired Glucose Tolerance (IGT) and
Diabetes Study [11] investigated 577 men and women
with IGT every 2 years over a 6-year period. The men
and women were randomized into one of four groups;
control, diet only, exercise only and diet plus exercise.
The cumulative incidences of T2DM after 6 years were
67.7% for control, 43.8% for diet only, 41.1% for exercise
only and 46.0% for diet and exercise. When adjusted for
difference in baseline BMI and fasting glucose the risk of
developing T2DM was decreased by 31% by diet only,
46% by exercise only and 42% by diet and exercise.
Furthermore, The Diabetes Prevention Program [12] a
large randomized clinical trial in adults at risk for the
development of T2DM, compared lifestyle intervention
with drug therapy. A total of 3234 participants were
assigned to one of three groups; control, metformin and
lifestyle intervention for an average of 2.8 years. The
lifestyle intervention was designed such that individuals
achieved and maintained weight loss of 7% and engaged
in physical activity for 150 min/week. Participants in
the lifestyle modification group lost significantly more
weight and increased physical activity to a greater
extent than either the metformin or control groups. Both
the metformin and lifestyle modification groups had a
significant reduction in the cumulative incidence of T2DM
compared to the control group (58% and 31%, lifestyle
and metformin respectively). Interestingly, the lifestyle
intervention was far more effective in reducing the risk of
developing T2DM than the metformin group.
In summary, it has been shown that obesity and physical
inactivity are risk factors for the development of T2DM.
Furthermore, 80% of type 2 diabetics are obese and
sedentary. It appears that a sedentary lifestyle (physical
inactivity) results in various symptoms of disease reduced
insulin sensitivity in the early stages and T2DM as
the disease is progressing. It is therefore important to
understand how inactivity causes IGT, reduced insulin
resistance and ultimately T2DM. In healthy humans,
skeletal muscle accounts for between 70 and 80%
of insulin-stimulated glucose uptake [13] and, skeletal
muscle is the principal peripheral site of insulin resistance
in T2DM [14,15]. The muscle is also responsible for the
most variable component of daily energy expenditure:
the thermic effect of exercise. This component can be
reduced to very low levels with a sedentary lifestyle.
The remainder of this review will therefore focus on the
underlying mechanisms within skeletal muscle thought
to link obesity and a sedentary lifestyle with insulin
resistance and the onset of T2DM.
Obesity, fatty acid uptake
and oxidation
Where adipose tissue is the principal organ for fatty
acid storage, skeletal and cardiac muscle are the most
important organs for fatty acid oxidation. Fatty acids
are mobilized from adipose tissue and transported to
the muscle for uptake and oxidation. In obesity, there
appears to be a mismatch between uptake of fatty
acids into skeletal muscle and oxidation, leading to
excessive accumulation of triacylglycerol and fatty acid
metabolites such as long chain acyl-CoAs, diacylglycerols
and ceramides in the sarcoplasm.
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Increased lipid accumulation within skeletal muscle
may occur through two mechanisms; either an increased
uptake and/or a decreased oxidation of fatty acids. In
obesity skeletal muscle is usually chronically exposed to
high plasma fatty acid concentrations which could drive
an increased uptake into the muscle. However, it has
been shown that the uptake of fatty acids (palmitate)
into giant vesicles prepared from skeletal muscle is
increased in insulin resistant skeletal muscle of obese
Zucker rats [16] as well as obese and type 2 diabetic
patients [17]. This increased uptake was observed even
when the palmitate concentration in the bathing medium
was equal and is suggested to be due to an increase in
proteins involved in fatty acid uptake. Both fatty acid
binding protein (FABPpm) [18] and fatty acid translocase
(FAT)/CD36 [17] are increased in obesity. In the case
of FAT/CD36 total protein content is not increased but
it is permanently translocated from intracellular depots
to the plasma membrane, thus facilitating fatty acid
uptake [19]. Additionally, a second likely explanation
for the accumulation of lipid within skeletal muscle
is a reduction in fat oxidation. Dobbins et al. [20]
reported that chronic inhibition (4-week) of fatty acid
uptake into the mitochondria using a pharmacological
inhibitor of carnitine palmitoyltransferase-1 resulted in
intramuscular triacylglycerol (IMTG) accumulation and
insulin resistance in rats. In humans a reduction in
postabsorptive fat oxidation has been reported frequently
in obesity and T2DM when compared with lean
individuals [21–25] and this reduction remains post
weight loss [26,27].
IMTG accumulation and insulin
resistance
It has been suggested that the increased availability and
uptake of circulating fatty acids alongside an impairment
in the ability to oxidize fat lead to the accumulation of
IMTG [20] and fatty acid metabolites such as long chain
acyl-CoAs, diacylglycerols and ceramides in obesity. Ele-
vated IMTG accumulation has been observed in obesity
[28,29] and there is a large body of evidence to suggest
that the accumulation of IMTG correlates with insulin
resistance and the development of T2DM [28,30–37].
In addition to these observational studies, intervention
studies that are typically associated with increased insulin
sensitivity such as weight loss [38] have shown reductions
in IMTG content [28]. Furthermore, increasing IMTG via
high fat feeding can decrease insulin sensitivity in rats
[39]. However, paradoxically, when endurance trained
athletes are included in these relationships the strong cor-
relation observed disappears [30,40] because endurance
trained athletes are highly insulin sensitive yet have ele-
vated IMTG content [30]. Further dissociation between
IMTG and insulin resistance becomes apparent when
examining recent exercise training data. Exercise train-
ing can increase insulin sensitivity despite an elevated
IMTG content in sedentary older adults [41] and seden-
tary overweight obese individuals [42]. As there is an
apparent dissociation between IMTG content and insulin
resistance it has been suggested that IMTG accumulation
is a surrogate marker for the accumulation of other lipid
intermediates that can modulate insulin signaling.
Fatty acid intermediates and insulin
signaling
Studies in which circulating plasma fatty acid concen-
trations have been acutely raised have lead to insulin
resistance in human skeletal muscle [19,43–45]. In addi-
tion chronic (4 d) lipid infusions have produced a similar
response [46]. Conversely, pharmacological reduction in
circulating plasma fatty acid concentrations using acip-
imox in individuals with chronically elevated fatty acid
concentrations has been shown to improve insulin resis-
tance overnight [47,48]. Furthermore, inactivation of
fatty acid transport protein 1, which is important in fatty
acid uptake and subsequent conversion to fatty acyl-CoA
within the skeletal muscle prevents the insulin resistance
observed with high fat feeding and lipid infusions in mice
[49].
Belfort et al. [43] reported that an elevation in cir-
culating fatty acids within the physiological range was
associated with a decrease in insulin-stimulated insulin
receptor tyrosine phosphorylation, insulin receptor sub-
strate (IRS)-1 tyrosine phosphorylation, IRS-1 associated
phosphatidylinositol (PI) 3-kinase activity, Akt serine
phosphorylation and glucose disposal rates. In addition
to the decreased insulin activation of IRS-1 tyrosine phos-
phorylation and IRS-1 associated PI3-kinase activity lipid
infusion is associated with an increase in long-chain acyl-
CoA and diacylglycerol content within the skeletal muscle
[50,51].
There is now an attractive hypothesis that suggests
a mechanistic link between the accumulation of fatty
acyl-CoAs and diacylglycerols and insulin resistance
(Figure 1). Skeletal muscle diacylglycerol content is
increased in human and animal models of insulin
resistance [50,51] and this can activate specific isoforms
of protein kinase C (PKC) which can inhibit insulin
signal transduction thought to be through serine
phosphorylation of IRS-1 [51]. Aguirre et al. [52] have
shown that phosphorylation on a specific serine site,
serine 307, of IRS-1 can block the phospho tyrosine
binding domain functions of the IRS-1 protein thereby
inhibiting the downstream signaling events such as PI3-
kinase activation.
Evidence implicating PKC comes from observations in
lipid induced insulin resistance models. Griffin et al. [53],
infused rats with lipid/heparin for 5 h and found that
the membrane fraction of PKC θ was increased four-
fold. This increase in membrane bound PKC θ was
associated with a blunting in insulin-stimulated IRS-1
tyrosine phosphorylation and a 50% reduction in insulin-
stimulated IRS-1-associated PI3-kinase activity. The same
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Figure 1. Lipids and insulin resistance. aPKC, atypical protein kinase C; IRS-1, insulin receptor substrate-1; PI3K,
phosphatidyl-3-kinase; PKB, protein kinase B; AS160, Akt substrate of 160 kDa; nPKC, novel isoforms of PKC; LC, long chain;
TAG, triacylglycerol; DAG, diacylglycerol; FAT/CD36, fatty acid translocase CD36. Dotted lines indicate inhibitory pathways, solid
lines indicate activation
is evident in human models. When healthy volunteers
were infused for 6 h with lipid/heparin a reduction in
glucose disposal was associated with a four-fold increase
in membrane bound PKC [50]. Moreover PKC θ knockout
mice are protected against fat induced insulin resistance
[54] and it has been demonstrated in cell lines [55–58]
and rats [53,59,60] that PKC can inhibit IRS-1 tyrosine
kinase activity and reduce insulin-stimulated glucose
uptake. In human skeletal muscle strips a cause and effect
relationship has been observed between PKC activation
and insulin-stimulated glucose uptake. Using human
skeletal muscle strips from lean and obese individuals
Cortright et al. demonstrated that in insulin resistant
muscle the addition of a PKC inhibitor could increase
glucose uptake. Conversely in insulin sensitive muscle
the addition of a PKC activator could depress insulin-
stimulated glucose uptake [61].
β-Oxidation and insulin signaling
In contrast to the lipid accumulation theory, Perdomo
et al. [62] demonstrated, in L6 myotubes, that an
increase in β oxidation induced by an overexpression
of carnitine palmitoyltransferase-1 increased insulin-
stimulated glucose uptake in the absence of any
perturbations in IMTG, diacylglycerol, ceramide or long
chain acyl-CoAs. In line with this finding, recent data
from Thyfault et al. [63] has indicated that elevations in
mitochondrial oxidative capacity following an acute bout
of exercise can increase insulin-stimulated glucose uptake
in the absence of any decrease in diacylglycerol or long
chain acyl-CoAs. Indeed, it was observed that long chain
acyl-CoAs increased following exercise. It has therefore
been speculated that acute exercise induces a coordinated
increase in β-oxidation with an up-regulation of the
tricarboxylic acid (TCA) cycle, such that complete fatty
acid oxidation takes place [64] and the resultant acetyl-
carnitines are immediately taken into the TCA cycle [63]
Conclusions
Being overweight or obese and leading a sedentary
lifestyle are two significant predictors of insulin resistance
and T2DM development. It would seem that the influence
of overweight/obesity is far greater than that of being
physically inactive when interpreting the magnitude of
relative risk of T2DM development. Lifestyle interventions
that include regular physical activity and dietary
modification can delay and even prevent the onset of such
diseases. A possible mechanism through which lifestyle
interventions exert their effects is thought to include an
increase in fat oxidation following a period of exercise
training. This mechanism has been shown to reduce the
accumulation of fatty acid species such as fatty acyl-CoAs,
diacylglycerols and ceramides within the skeletal muscle,
thus attenuating the inhibition on the insulin signaling
pathway. Moreover, an early response to exercise training
could include a coordination of the increase in β-
oxidation with an up-regulation of the TCA cycle leading
to a decrease in the accumulation of diabetogenic
β-oxidation intermediates.
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